

Remarks

Claims 9, 13, 14, and 31-58 are pending in the application after entry of the present amendment. Claim 36 has been amended to recite that the chimeric anti-WISP-1 antibody comprises a fragment from the 3D11, 11C2, 9C10, 5D4, or 9C11 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number PTA-4624, PTA-4628, PTA-4626, PTA-4625, or PTA-4627, respectively, which specifically binds to WISP-1 polypeptide. Claim 37, dependent on claim 36, has been amended to correct for improper antecedent basis resulting from amendment of claim 36. Claims 14, 35, and 40 have been amended to refer to pancreatic cancer. Support for this amendment is found on page 24, lines 1-8, of the specification as filed.

New claims 42-58 are added after entry of this amendment. These claims find support in the specification as filed, for example at page 8, line 17, through page 9, line 12, Examples 10-16, page 80, lines 10-41, and in the claims as originally filed.

No new matter is added through the amendments presented herein. Applicant respectfully requests reconsideration of the present application in view of the foregoing amendments and in view of the reasons that follow.

Examiner Interview

Applicant thanks Examiner Gamett for initiating the telephonic interviews conducted with Applicant's representative Traci H. Ropp (Reg No. 44,307) on March 31, 2008 and April 9, 2008. The first interview was directed toward discussion of the amendments now presented in claim 35. The second interview was directed toward the possibility of reintroducing claims in this case directed to the anti-WISP-1 antibodies recited in the pending method claims. These antibody claims have been added as claims 43-58. Similar antibody claims are currently pending in related case US patent application serial number 11/105,876. Accordingly, Applicant will cancel these antibody claims in USSN 11/105,876.

Conclusion

Applicant believes that the pending claims are in condition for allowance, and respectfully request that a timely Notice of Allowance be issued in this case. If in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at the number indicated below.

The fee associated with the addition of new claims is submitted with this paper. Applicant believes that no other fees are required in connection with this paper. However, the Commissioner is authorized to charge our Deposit Account 07-0630 for any fees required or credits due and any extensions of time necessary to maintain the pendency of this application.

Respectfully submitted,

GENENTECH, INC.

Date: April 14, 2008

By: 

Traci H. Ropp
Reg. No. 44,307
Telephone No. (650) 467-0481